17:32 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Eye infection company Okogen raises $10M series A

Ocular infection company Okogen Inc. (San Diego, Calif.) raised $10 million on Feb. 27 in a series A round from Brandon Capital through the VC's Medical Research Commercialisation Fund. Okogen plans to start a Phase II...
13:31 , Feb 27, 2018 |  BC Extra  |  Financial News

Eye infection company Okogen raises $10M series A

Ocular infection company Okogen Inc. (San Diego, Calif.) raised $10 million in a series A round from Brandon Capital through the VC's Medical Research Commercialisation Fund. Okogen plans to start a Phase II trial of lead...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Onconase cytotoxic pancreatic RNase data

ACEL presented interim results of an ongoing Phase II trial at the International Mesothelioma Conference in Philadelphia. A total of 63 patients received 480 µg/m2 Onconase weekly by IV, 26 of whom are still alive....
07:00 , Aug 2, 2010 |  BC Week In Review  |  Clinical News

Tamir preclinical data

Onconase produced a selectivity index (SI) score of 41 against the SARS virus in vitro. SI is a measure of EC50 concentration and EC90 cell inhibitory concentration in stationary cells (SI=EC50/EC90). In 2008, Tamir (formerly...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Financial News

Alfacell completes private placement of units

Alfacell Corp. (Pink:ACEL), Somerset, N.J.   Business: Cancer   Date completed: 10/20/09   Type: Private placement of units   Raised: $3.3 million   Units: 65   Price: $50,000 (unit)   Investors: Europa International; Unilab; company management; private investor   Note: Each unit comprised...
07:00 , Apr 6, 2009 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/08 1/9/09 Array BioPharma Inc. (NASDAQ:ARRY) 10% to ~350 ...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Biogen Idec biopharmaceuticals news

Biogen Idec said Carl Icahn plans to nominate a slate of four directors at the company's annual shareholder meeting, which is typically held in June. The nominees include Alexander Denner, managing director of a number...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

Alfacell cancer news

Alfacell will restructure and reduce headcount by an undisclosed number. The move follows an FDA recommendation for an additional Phase III trial of the company's lead compound, Onconase ranpirnase, to treat unresectable malignant mesothelioma....
08:00 , Dec 22, 2008 |  BC Week In Review  |  Company News

Alfacell management update

Alfacell Corp. (NASDAQ:ACEL), Somerset, N.J.   Business: Cancer   Resigned: Lawrence Kenyon as president and CFO to become EVP of finance at Par Pharmaceutical Inc.; he will remain on the board and serve as acting president and...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

Onconase ranpirnase regulatory update

Alfacell said completing its rolling NDA for Onconase ranpirnase to treat unresectable malignant mesothelioma would be delayed from this month after preparing materials for the submission took more time than expected. The company said it...